DNA topoisomerase II betaGenealiases: BILU · TOPIIB · top2beta
Q-omics provides the consensus-scored TOP2B profile across patient tissues and cancer cell-line models. TOP2B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TOP2B is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, TOP2B protein abundance shows 36,587 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, KIRC, and GBM as cancer lineages where TOP2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOP2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOP2B survival associations across molecular data types. TOP2B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOP2B RNA expression–survival associations across cancer types. High TOP2B expression shows unfavorable associations in LIHC, ACC, MESO and SARC, but favorable associations in KIRC and UCS. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TOP2B RNA expression.
This table summarizes TOP2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TOP2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOP2B shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in LIHC, CHOL and BRCA. The KIRC box plot shows higher TOP2B RNA expression in normal versus tumor tissue (log2 FC = −0.907, t-test p < 0.001).
This table shows molecular features associated with TOP2B in patient tissues and cancer cell lines. In patient samples, TOP2B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TOP2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
